Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes

Diabetes Care

Volumn 37, Issue 3, 2014, Pages 666-670

  Sarkar, Gayatri ^a   Alattar, May ^a   Brown, Rebecca J ^a   Quon, Michael J ^b   Harlan, David M ^c   Rother, Kristina I ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; PEPTIDE; VENOM;

ADJUVANT THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT REDUCTION; YOUNG ADULT; BLOOD; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION; DRUG EFFECTS; HYPERGLYCEMIA; INSULIN RESISTANCE; METABOLISM; PHYSIOLOGY; POSTPRANDIAL STATE;

ADULT; BLOOD GLUCOSE; BODY WEIGHT; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PEPTIDES; POSTPRANDIAL PERIOD; VENOMS;

EID: 84896702500     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-1473     Document Type: Article

References (14)

1. Raman VS, Mason KJ, Rodriguez LM, et al. The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care 2010;33:1294-1296
2. Rother KI, Spain LM, Wesley RA, et al. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care 2009;32:2251-2257
3. Dupŕe J, Behme MT,McDonald TJ. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J Clin Endocrinol Metab 2004;89:3469-3473
4. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008; 294:E15-E26
5. Brown RJ, Wijewickrama RC, Harlan DM, Rother KI. Uncoupling intensive insulin therapy from weight gain and hypoglycemia in type 1 diabetes. Diabetes Technol Ther 2011;13:457-460
6. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005;54:1-7
7. Edwards CM, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. AmJ Physiol Endocrinol Metab 2001;281:E155-E161
8. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88:3082-3089
9. Gromada J, Franklin I, Wollheim CB. Alphacells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 2007;28:84-116
10. Robertson RP. The welcome resurgence of the a-cell: a pro glucagon commentary. Diabetes 2010;59:2735-2736
11. Bergman BC, Howard D, Schauer IE, et al. Features of hepatic and skeletal muscle insulin resistance unique to type 1 diabetes. J Clin Endocrinol Metab 2012;97:1663-1672
12. Gedulin BR, Nikoulina SE, Smith PA, et al. Exenatide (exendin-4) improves insulin sensitivity and beta-cell mass in insulinresistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 2005;146:2069-2076
13. Idris I, Patiag D, Gray S, Donnelly R. Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1. Biochem Pharmacol 2002; 63:993-996
14. Schauer IE, Snell-Bergeon JK, Bergman BC, et al. Insulin resistance, defective insulinmediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: the CACTI study. Diabetes 2011;60:306-314